Literature DB >> 1531924

Prevalence of dermatophyte onychomycosis in the United Kingdom: results of an omnibus survey.

D T Roberts1.   

Abstract

A computer omnibus survey to determine the prevalence of onychomycosis in the United Kingdom was carried out in the early part of 1990. A total population of 9332 adults, aged 16 years and over, was interviewed face-to-face, and a questionnaire completed, which consisted of questions and photographs of various nail dystrophies, including onychomycosis. The results in the population surveyed revealed a prevalence of dermatophyte nail infection of 2.8% in men and 2.6% in women. In the group aged 16-34 years, the prevalence rate was 1.3%; this increased to 2.4% in the group aged 35-50 years, and to 4.7% in those aged 55 years or over. Of those found to have onychomycosis, 27% had sought advice from a chiropodist and less than 12% had consulted a specialist. These results suggest that nearly 1.2 million people in the UK have a fungal nail infection and the majority had not sought medical advice, although over 80% stated that they would do so if they were aware that their nail disorder was of fungal origin. A similar proportion would wish to be treated if an effective treatment was available.

Entities:  

Mesh:

Year:  1992        PMID: 1531924     DOI: 10.1111/j.1365-2133.1992.tb00005.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN: 0007-0963            Impact factor:   9.302


  49 in total

1.  Extracts from "Clinical evidence": Athlete's foot and fungally infected toenails.

Authors:  F Crawford; R Hart; S E Bell-Syer; D J Torgerson; P Young; I Russell
Journal:  BMJ       Date:  2001-02-03

2.  Inappropriate use of oral terbinafine in family practice.

Authors:  Michael Wilcock; John Hartley; David Gould
Journal:  Pharm World Sci       Date:  2003-02

Review 3.  Onychomycosis in the elderly.

Authors:  A K Gupta
Journal:  Drugs Aging       Date:  2000-06       Impact factor: 3.923

4.  World at work: Evidence based risk management of nail dust in chiropodists and podiatrists.

Authors:  J G Burrow; N A McLarnon
Journal:  Occup Environ Med       Date:  2006-10       Impact factor: 4.402

5.  Cost of treatment for onychomycosis. Data from a 9-month observational study.

Authors:  D M Stier; C Henke; J Schein; J Doyle; W H Schonfeld; J Broering
Journal:  Pharmacoeconomics       Date:  2001       Impact factor: 4.981

Review 6.  Clinical and economic factors in the treatment of onychomycosis.

Authors:  T R Einarson; A K Gupta; N H Shear; S Arikian
Journal:  Pharmacoeconomics       Date:  1996-04       Impact factor: 4.981

7.  In vitro antifungal activity of ME1111, a new topical agent for onychomycosis, against clinical isolates of dermatophytes.

Authors:  M Ghannoum; N Isham; L Long
Journal:  Antimicrob Agents Chemother       Date:  2015-06-08       Impact factor: 5.191

8.  Double blind, randomised study of continuous terbinafine compared with intermittent itraconazole in treatment of toenail onychomycosis. The LION Study Group.

Authors:  E G Evans; B Sigurgeirsson
Journal:  BMJ       Date:  1999-04-17

9.  Nondermatophytic moulds as a causative agent of onychomycosis in tehran.

Authors:  Shahindokht Bassiri-Jahromi; Ali Asgar Khaksar
Journal:  Indian J Dermatol       Date:  2010 Apr-Jun       Impact factor: 1.494

10.  Comparison of diagnostic methods in the evaluation of onychomycosis.

Authors:  Iman Haghani; Tahereh Shokohi; Zohreh Hajheidari; Alireza Khalilian; Seyed Reza Aghili
Journal:  Mycopathologia       Date:  2013-02-01       Impact factor: 2.574

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.